TGFB1 and osteogenesis imperfecta: Denoting the interest in exploring the inhibition of TGF-β pathway in OI, a phase I clinical trial evaluating the safety and efficacy of fresolimumab, a human monoclonal antibody, that recognizes all TGF-β isoforms, is currently being assessed in adult patients (NCT03064074).